Trial Profile
Phase I/II Study of Cisplatin Plus Romidepsin and Nivolumab in Metastatic Triple Negative Breast Cancer or BRCA Mutation-Associated Locally Recurrent or Metastatic Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 03 May 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Romidepsin (Primary) ; Cisplatin
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- 25 Apr 2023 Planned End Date changed from 1 Jul 2022 to 1 Jul 2025.
- 25 Apr 2023 Planned primary completion date changed from 1 Jul 2022 to 1 Dec 2024.
- 19 Nov 2021 Planned End Date changed from 1 Oct 2021 to 1 Jul 2022.